Immix Biopharma Investor Presentation Deck

IMX-120 Opportunity: Inflammatory Bowel Disease (IBD) Market Treatment Arm Placebo Company Clinical Remission Rate at Wk 8 Moderate-to-severe ulcerative colitis (who received concurrent treatment with oral corticosteroids or immunosuppressants) 16.5% 9.3% Humira/adalimumab vs. placebo abbvie Sources: Adapted from Sandborn et al., 2012, Sands et al., 2019, FDA Entyvio® Prescribing Label Clinical Remission Rate at Wk 8 Moderate-to-severe ulcerative colitis 15.6% 5.3% Stelara/ustekinumab vs. placebo Johnson & Johnson ●●● IMMIX S BIOPHARMA Clinical Remission Rate at Wk 6 Moderately to severely active ulcerative colitis 17% 5% Entyvio/vedolizumab vs. placebo Takeda 57

View entire presentation